UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company with a market capitalization of $483 million and impressive gross profit margins of 90%, recently reported insider transactions by Jason Drew ...

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Chemoablation with mitomycin gel (Jelmyto) for low-grade upper tract urothelial cancer led to a 3-year recurrence-free ...

PRINCETON, N.J. - Recent findings from a study on UroGen Pharma Ltd.'s (NASDAQ: URGN) JELMYTO (mitomycin) for pyelocalyceal solution suggest its effectiveness in long-term disease control for patients ...

PRINCETON, N.J. - Recent findings from a study on UroGen Pharma Ltd.'s (NASDAQ: URGN) JELMYTO (mitomycin) for pyelocalyceal solution suggest its effectiveness in long-term disease control for ...

The long-term study evaluated 56 patients who achieved complete response after treatment with JELMYTO from 15 high-volume academic and community centers and helps characterize how urologists are ...

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses AD04’s development timeline and next steps towards approval for alcohol ...

ImmunityBio aims to expand Anktiva's approval for BCG-unresponsive NMIBC with papillary tumors, potentially reducing radical cystectomy rates. The QUILT-3.032 trial demonstrated promising disease-free ...

"We're very much looking forward to the new data that'll be presented, hopefully, within the next year, to see where this falls in the grand scheme of the all the new drugs coming into play here," ...